|
Thursday's Pick!! Sign Up For The Hottest Newsletter!! WZE "Wizzard Media Launches 24 New iPhone Apps "
(M2 PressWIRE Via Acquire Media NewsEdge) STOCK MARKETING INC PRESENTS :
(NYSE: WZE - Wizzard Software Corp.)
(NASDAQ: TLVT - Telvent GIT S.A.)
(NASDAQ: PLCM - Polycom, Inc.)
(NASDAQ: IXYS - IXYS Corp.)
(NASDAQ: AMGN - Amgen Inc.)
(NASDAQ: CMTL - Comtech Telecommunications Corp.)
www.StockMarketingInc.cm
To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com
email us!! info@StockMarketingInc.com or call 1-866-583-8960
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NYSE: WZE - Wizzard Software Corp.)
LATEST NEWS!!
Wizzard Media Launches 24 New iPhone Apps
PITTSBURGH, Nov 05, 2009 -- Wizzard Media (NYSE Amex: WZE), the world's largest podcasting network, today announced the launch of 24 new iPhone(R) Apps available for sale in the App store including Investors Business Daily Editorials and Alaska HDTV. The average price for the new Apps is $1.99.
The newly launched Apps are iPhone companion Apps for popular podcasts on the Wizzard Media Network, offering audiences one-click access to the podcast directly on their iPhone or iPod Touch(R), bonus content and new social communication features creating an unprecedented level of audience engagement.
Wizzard recently announced 2009 third quarter network numbers of 12,281 podcasts downloaded 332 million times in the quarter by over 18 million unique monthly audience members. Approximately 70% of the audience for podcasts subscribe through iTunes(R) from which users download podcasts for their iPhone and iPod(R). Until recently, Wizzard's only means to derive revenues was through podcast publishing services as well as advertising sales.
With the launch of the iPhone App store in iTunes, Wizzard created a unique iPhone App that can be quickly customized for each podcast and allows podcast publishers to generate a new revenue stream by marketing their own iPhone App directly to their audience. Wizzard shares in this revenue with the podcast publisher. Now, with Wizzard's unique podcast companion App for the iPhone, participating podcasts can market their customized App to their audience and then drive future reoccurring episode and subscription sales through a process called in-App purchasing.
Analysts project the App market to be a $1.0 billion market today, headed for $4.0 billion by 2012. With the holiday season approaching and the recent launch of the iPhone in China, Wizzard's Management believes the number of people using iPhones and iPod Touches to consume podcasts and interact with Apps will continue to grow well beyond the current 50 million user base.
Having launched the first podcast App only 95 days ago, Wizzard Media already has launched 70 iPhone Apps with 60 more Apps awaiting approval. Additionally, Wizzard has exclusively licensed 12 high quality, game type Apps and is currently marketing them through targeted podcasts across the Wizzard Media Network. Select podcast Apps on the Wizzard Network have already helped to convert approximately 15% of their audience from free, to paid, in the first 75 days since launch.
"We think our podcast companion App initiative is a game changer for the podcasting industry. We believe the next great opportunity on the web for media is the seamless combination of three trends -- publishing services, advertising and micropayments for App sales," says Dave Mansueto, co-founder Wizzard Media. "Now, podcasting becomes a platform that converts audiences to revenue, accelerated by the micropayment billing process that Apple has created with the App store. We believe this new process is the model for how digital media is published, audiences are grown and revenues derived." "We know there is strong demand for the podcasts we distribute seeing downloads grow from 400 million to well over 1 billion in the last three years and monthly audiences grow from 4 million to 18 million," says Laurie Sims, President of Wizzard Media. "Now that we have a method to charge for podcast content and subscriptions, we believe there is dramatic change ahead for the podcast industry. Unlike most Apps in the App store, podcasters have a distinct advantage to successfully market their App in iTunes due to the fact that they have already built a substantial audience for their product through iTunes." About Wizzard Media: Wizzard Media provides publishing and distribution services to podcasters and monetization services for podcasters. Wizzard Media is the industry's leading podcasting network with an unprecedented 1.2 billion download requests in 2008. Podcasts are a means for independent and professional content creators to publish audio and video shows for the world to enjoy over the Internet or on mp3 players, such as the Apple iPod(R), iPhone(R) and the Microsoft Zune(R). Podcasting is a relatively new phenomenon, but Wizzard Media collectively broadcasts millions of podcast downloads per day through media aggregators like Apple's iTunes and Microsoft's Zune Marketplace. For more information, please visit www.wizzardsoftware.com/media . Wizzard Media is a division of Wizzard Software, a leader in speech technology distribution and development.
------------------------------------------------------------------------------------------------------------------------------------------------------------ (NASDAQ: TLVT - Telvent GIT S.A.)
LATEST NEWS!!
Telvent Achieves Internationally Recognized Certification Thanks to Its Information Security Systems Management Standards
MADRID, Spain, Nov 5, 2009 -- Telvent (Nasdaq:TLVT), the IT company for a sustainable and secure world, has announced today that its Global Services division has achieved the certification of its procedures related to the Information Security Management System (ISMS), in accordance with UNE-ISO/IEC 27001:2005 for Information Technology Services. The certification is internationally recognized in the management of information security and it is designed to ensure adequate security controls that protect information assets and provide confidence to current and potential business customers.
The certification assesses the technological outsourcing of information systems in the stages of definition, planning, management, control and improvement of backup, Internet access and monitoring. After completing the external certification audit of its security management model and provision of services, Telvent was commended for its capacity for continuous improvement and learning.
Manuel Sanchez, Telvent's Chairman and CEO, said, "It is our belief that to provide the best in Information Technology services, Telvent must provide our customers with more than the sole implementation of the latest technological advances. It is essential to have a clear and adequate strategy to ensure the security of the information as a valuable asset to our customers. This has become an essential priority for us, with a clear impact on the continuous improvement in our processes that we validate in the market under international standards." During the last few years, Telvent has won various international ISO standards certifications, among others, from various institutions such as the one that Telvent obtained from the British Standard Institute (BSI); the ISO 9001, for Quality Management; the ISO 14001, for Environmental Management; UNE-ISO/IEC 20000-1:2005; as well as evaluation methods of business excellence based in EFQM (European Foundation for Quality Management).
About Telvent Telvent (Nasdaq:TLVT) is a global IT solutions and business information services provider that improves the efficiency and reliability of the world's premier organizations. The company serves markets critical to the sustainability of the planet, including the energy, transportation, agriculture, and environmental sectors. (www.telvent.com) ------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: PLCM - Polycom, Inc.)
LATEST NEWS!!
Polycom SoundStation IP 6000 and IP 7000 Conference Phones Are Now Rated Avaya Compliant
Award-Winning Polycom HD Voice Conference Phones Now Compatible With Avaya Aura(TM) Communication Manager, Avaya IP Office and Avaya Integral Platforms
PLEASANTON, CA, Nov 05, 2009 -- Polycom, Inc. (NASDAQ: PLCM), the global leader in telepresence, video and voice communications solutions, today announced that its standards-based Polycom SoundStation IP 6000 and SoundStation IP 7000 conference phones, featuring Polycom HD Voice(TM), are compliant with the Avaya Aura Communication Manager, Avaya IP Office and Avaya Integral solutions from Avaya, a leading global provider of business communications applications, systems and services.
The SoundStation(R) IP 7000 and IP 6000 -- two next-generation IP conference phones -- offer groundbreaking Polycom features including Polycom HD Voice(TM) technology and a sleek new design. The SoundStation IP 7000 is an ideal upgrade for executive offices, conference rooms and board rooms, while the SoundStation(R) IP 6000 is suited for managerial offices and small to mid-sized conference rooms. Additionally, Avaya is offering the Avaya 1692 IP Speakerphone, which is manufactured by Polycom. The Avaya 1692 IP Speakerphone provides the convenience and productivity benefits inherent in a powerful, hands-free conference phone. It delivers the extensive set of Avaya Aura(TM) features directly to small, midsize and large conference rooms.
Polycom is a Platinum member of the Avaya DevConnect program -- an initiative to develop, market and sell innovative third-party products that interoperate with Avaya technology and extend the value of an organization's investment in its network. As a Platinum member of the program, Polycom is eligible to submit products for compatibility testing by the Avaya Solution Interoperability and Test Lab. There a team of Avaya engineers develops a comprehensive test plan for each application to verify whether it is Avaya compliant. Doing so ensures businesses can confidently add best-in-class capabilities to their network without having to replace their existing infrastructure -- speeding deployment of new applications and reducing both network complexity and implementation costs.
"By offering compliance testing to the many innovative companies like Polycom who are members of our DevConnect program, Avaya promotes fully interoperable solutions that help businesses unleash powerful new possibilities," said Eric Rossman, vice president, developer relations and technical alliances, Avaya. "They are able to use unified communications capabilities to connect employees and customers to information from wherever they are, over whatever device they have available -- getting more out of their multivendor network and delivering new value to their bottom line." ------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: IXYS - IXYS Corp.)
LATEST NEWS!!
Westcode Announces New Insulated Water Cooler for Very Large Power Semiconductors
BIEL, Switzerland, Nov 05, 2009 -- IXYS Corporation (NASDAQ:IXYS) announced that its wholly owned UK subsidiary, Westcode Semiconductors Limited, has launched a new addition to its range of power semiconductor water coolers. The insulated Aluminium Nitride cooler has a 133mm diameter contact plate, making it suitable for press-pack devices with electrode contacts up to 125mm diameter.
The new coolers incorporate geometric water channels designs to ensure low values of thermal resistance even at moderate coolant flows, while retaining a robust structure compatible with the high clamping force required by large area power semiconductors. The geometric design used for the water channels also ensures a highly uniform cooling over the entire surface area. Typical cooler to input water thermal resistance for flow rate of 10 liters/minute are 5.2 Deg.K/kW (two coolers + 1 semiconductor) and 6.1 Deg.K/kW (three coolers + 2 semiconductors). Isolation voltage between water and the device is 10kV (RMS for 1minute).
"These isolated coolers allow the implementation of very high power density high voltage solutions, without the need for expensive and complex de-ionised water systems," commented Ashley Golland, Global High Power Applications Manager. "In applications such as traction drives, marine drives and wind turbines, the existing liquid coolant systems may be extended to the power electronics resulting in lower system cost, weight and noise levels and increased energy efficiency." The high quality surface finish, typical flatness 10 micrometers, makes the cooler ideal for use with Westcode's high performance Press-pack IGBTs (T1800EB45A, T2250AB25E & T2400EB45E). Additionally the coolers are suitable for use with all large area power devices, such as thyristors and Rectifier diodes, with contact electrodes from 90mm to 125mm diameter and clamping force up to 13 N per square millimeter. Typical applications include Megawatt drives and high power rectifiers, such as chemical power supplies or trackside substations, as well as all applications in the utilities field. The standard cooler part number is XW180GN25A, for more detail and information on standard bus bar connections, please consult the factory.
More information is available on the Westcode website at www.westcode.com or please contact us at (email: WSL.sales@westcode.com) or telephone: +44 (0) 1249 444524 for quotation.
About Westcode Located in Chippenham, England, Westcode Semiconductors Ltd is a leading manufacturer of very high power thyristors, SCRs and rectifiers ranging up to 6500 Volts and 15,000 Amps. Westcode continues to supply high technology components for a wide range of applications such as welding, AC and DC drives, rectifier supplies, uninterruptible power supplies, motor soft starts, transportation, induction heating, power conditioning, high energy physics and many other industrial uses.
About IXYS Corporation Since its inception in 1983, IXYS Corporation has been developing technology-driven products to improve power conversion efficiency, generate solar and wind power and provide efficient motor control for industrial applications. IXYS, and its subsidiary companies, offer a diversified product base that addresses worldwide needs for power control, electrical efficiency, renewable energy, telecommunications, medical devices, flexible displays and RF power.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: AMGN - Amgen Inc.)
LATEST NEWS!!
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer --Phase 3 Results Reinforce Importance of KRAS Status
THOUSAND OAKS, Calif., Nov 05, 2009 via COMTEX/ -- Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.
The prospective analysis of the 203 study showed that Vectibix, when added to a FOLFOX chemotherapy regimen in patients with KRAS wild-type mCRC, resulted in a median overall survival of 23.9 months compared to 19.7 months for patients treated with FOLFOX alone. The median overall survival difference of 4.2 months in the Vectibix arm did not reach statistical significance (HR=0.83, p=0.072).
"As we previously announced, the 203 study met its primary endpoint of progression-free survival in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "While not statistically significant, we are also encouraged by the positive trend of the data for overall survival for these patients treated with Vectibix." Overall survival appeared to be reduced in patients with KRAS mutant tumors receiving Vectibix. Although not statistically significant, this result emphasizes the importance, as described in product labeling, of ensuring that patients receiving Vectibix( )do not bear tumors containing KRAS mutations.
Overall, the adverse event profile was as anticipated for an anti-EGFR antibody in combination with oxaliplatin-based chemotherapy, including known events such as rash, diarrhea and hypomagnesemia. Vectibix-related grade 3 infusion reactions were reported for two patients (less than 1 percent).
Originally designed to compare the treatment effect in the overall population, the study was amended to analyze outcomes with respect to the presence or absence of activating mutations in KRAS in the tumor itself. Tumor KRAS status was ascertained in more than 90 percent of the 1,183 patients enrolled in the trial.
Available results from the trial were presented earlier this year at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany showing that Vectibix significantly improved median progression-free survival by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, in patients with KRAS wild-type mCRC (primary endpoint). Further, the addition of Vectibix to chemotherapy also improved response rate in the KRAS wild-type patient population as measured by blinded central review (55 percent versus 48 percent in the FOLFOX only arm).
The data for the 203 study has been submitted for consideration of presentation at the American Society of Clinical Oncology - The Gastrointestinal Cancers Symposium Meeting for 2010.
Study Design Patients enrolled in the "203" or PRIME trial (Panitumumab Randomized trial in combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy) were randomized to receive either 6.0 mg/kg of Vectibix and FOLFOX4 once every two weeks (Q2W) or FOLFOX4 alone Q2W. The primary endpoint of the study is progression-free survival by KRAS status and secondary endpoints include overall survival, objective response rate, time to progression, duration of response and safety.
About KRAS Results from studies performed over the last twenty-five years indicate that KRAS plays an important role in cell growth regulation. In mCRC, EGFR transmits signals through a set of intracellular proteins. Upon reaching the nucleus, these signals instruct the cancer cell to reproduce and metastasize, leading to cancer progression. Anti-EGFR antibody therapies work by blocking the activation of EGFR, thereby inhibiting downstream events that lead to malignant signaling. However, it is hypothesized that in patients whose tumors harbor a mutated KRAS gene, the KRAS protein is always turned "on," regardless of whether the EGFR has been activated or therapeutically inhibited. KRAS mutations occur in approximately 40 - 50 percent of mCRC.
About Colorectal Cancer Colorectal cancer is the fourth most common cancer in men and the third most common cancer in women worldwide. In 2007, approximately 1.2 million cases of colorectal cancer were expected to occur globally. With more than 630,000 deaths worldwide per year, it is the second leading cause of cancer-related death in the Western world. The highest incidence rates are found in Japan, North America, parts of Europe, New Zealand, and Australia, and rates are low in Africa and South-East Asia.( ) Rates are substantially higher in men than in women.
About Vectibix Vectibix is the first fully human anti-EGFR antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix was approved in the United States in September 2006 as a monotherapy for the treatment of patients with EGFR expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based on progression-free survival. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix. Vectibix has not shown a treatment benefit for patients whose tumors had KRAS mutations in codon 12 or 13.
In December 2007, the EMEA granted a conditional marketing authorization for Vectibix as monotherapy for the treatment of patients with EGFR-expressing mCRC with wild-type KRAS genes after failure of standard chemotherapy regimens. Vectibix has been launched in over 20 countries, Switzerland, Australia and Canada. Applications in the rest of the world are pending.
Important Product Safety Information Dermatologic Toxicity: Dermatologic toxicities occurred in 89 percent of patients and were severe (NCI-CTC grade 3 and higher) in 12 percent of patients receiving Vectibix monotherapy. Withhold Vectibix for dermatologic toxicities that are grade 3 or higher or are considered intolerable. If toxicity does not improve to Infusion Reactions: Severe infusion reactions occurred in approximately 1 percent of patients. Severe infusion reactions included anaphylactic reactions, bronchospasm, and hypotension. Although not reported with Vectibix, fatal infusion reactions have occurred with other monoclonal antibody products. Stop infusion if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, permanently discontinue Vectibix.
About Amgen Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
------------------------------------------------------------------------------------------------------------------------------------------------------------
(NASDAQ: CMTL - Comtech Telecommunications Corp.)
LATEST NEWS!!
Comtech Telecommunications Corp. Wins $1.6 Million SATCOM Equipment Order to Support Cellular Backhaul-Based Service Expansion in Asia
MELVILLE, N.Y., Nov 5, 2009 -- Comtech Telecommunications Corp. (Nasdaq:CMTL) announced today that its Tempe, Arizona-based subsidiary, Comtech EF Data Corp., won a $1.6 million order for satellite communications equipment. An Asian mobile operator will utilize the equipment to support satellite-based cellular backhaul service expansion.
The order specifies Comtech EF Data's CDM-600 Satellite Modems and redundancy switches, plus the CX-U Series cellular backhaul platform from its subsidiary, Memotec, Inc. The CDM-600 is an open network satellite modem compliant with IESS-308/309/310/314/315 from 64 kbps through T2 and E2. The architecture is firmware and FPGA-based, and the modem offers exceptional flexibility and performance in a 1RU enclosure.
Memotec's CX-U Series is a dedicated cellular backhaul platform that delivers Radio Access Network optimization and A/E voice trunks compression. The CX-U reduces the bandwidth required to backhaul cellular traffic, therefore avoiding costly forklift network upgrades. The result is a significant reduction in operating and capital expenses.
"Globally accepted as the premier provider of bandwidth-efficient satellite modems and Abis bandwidth optimization equipment, our solutions enable cost-effective service expansion by operators," said Fred Kornberg, President and Chief Executive Officer of Comtech Telecommunications Corp.
Memotec, Inc., a subsidiary of Comtech EF Data Corp., is an innovative supplier of optimization solutions for cellular backhaul networks. Its flagship product, the CX Series, enables enterprises, GSM, CDMA and 3G operators to dramatically reduce network operating expenses by cutting transmission costs and extending the service capabilities for evolving networks. Memotec's solutions are proven globally with equipment deployed in over 1,000 operational cellular sites throughout Latin America, the Middle East, Africa and Asia. Please visit www.memotec.com for more information.
Comtech EF Data Corp. manufactures a broad spectrum of satellite communications products, including Satellite Modems, Bandwidth & Capacity Management, TCP/IP Performance Enhancement Proxies, Encapsulators, Receivers, Converters, Amplifiers, Transceivers and Terminals. All products meet or exceed the standards published by worldwide and regional satellite networks. Please visit www.comtechefdata.com for more information.
Comtech Telecommunications Corp. designs, develops, produces and markets innovative products, systems and services for advanced communications solutions. The Company believes many of its solutions play a vital role in providing or enhancing communication capabilities when terrestrial communications infrastructure is unavailable, inefficient or too expensive. The Company conducts business through three complementary segments: telecommunications transmission, mobile data communications and RF microwave amplifiers. The Company sells products to a diverse customer base in the global commercial and government communications markets. The Company believes it is a market leader in the market segments that it serves.
------------------------------------------------------------------------------------------------------------------------------------------------------------
About StockMarketingInc.com
StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.
((Comments on this story may be sent to info@m2.com))
(c) 2009 M2 COMMUNICATIONS
[ Back To Satellite.tmcnet.com's Homepage ]
|